Commentary on “Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al.

Ítems similars

• Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19”
  per: Mastellos, Dimitrios C., et al.
  Publicat: (2021)
• Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy
  per: Mastellos, Dimitrios C., et al.
  Publicat: (2020)
• What happens in Brazil? A pandemic of misinformation that culminates in an endless disease burden
  per: Cardoso, Cristina Ribeiro de Barros, et al.
  Publicat: (2020)
• Genetic diversity in populations of African mahogany (Khaya grandioliola C. DC.) introduced in Brazil
  per: Soares, Sabrina Delgado, et al.
  Publicat: (2020)
• Clinician's Commentary on Oliveira et al.(1)
  per: Lima, Vanessa Pereira, et al.
  Publicat: (2018)